An economic analysis of cell-free DNA Non-invasive prenatal testing in the US general pregnancy population

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Benn, Peter ^a   Curnow, Kirsten J ^b   Chapman, Steven ^c   Michalopoulos, Steven N ^d   Hornberger, John ^d,e   Rabinowitz, Matthew ^c  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b ILLUMINA INC   (United States)

^c NATERA INC   (United States)

^d Cedar Associates ^*  (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE DNA; DNA; UNCLASSIFIED DRUG;

ADULT; ANEUPLOIDY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; DNA DETERMINATION; FEMALE; FETUS; FETUS WASTAGE; FIRST TRIMESTER PREGNANCY; HUMAN; INTERMETHOD COMPARISON; MONOSOMY X; NON INVASIVE PRENATAL TEST; PREGNANCY TERMINATION; PRENATAL SCREENING; SENSITIVITY AND SPECIFICITY; THIRD TRIMESTER PREGNANCY; TRISOMY 13; TRISOMY 18; TRISOMY 21; UNITED STATES; CELL FREE SYSTEM; ECONOMIC MODEL; ECONOMICS; GENETICS; PREGNANCY; PRENATAL DIAGNOSIS; PROCEDURES; SECOND TRIMESTER PREGNANCY;

ANEUPLOIDY; CELL-FREE SYSTEM; DNA; FEMALE; HUMANS; MODELS, ECONOMIC; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; UNITED STATES;

EID: 84941337904     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0132313     Document Type: Article

References (42)

1. Centers for Disease Control and Prevention. Vital Stats-Births 2014 [21 October 2014]. Available: http://www.cdc.gov/nchs/data-Access/vitalstats/VitalStats-Births.htm.
2. American Congress of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 77: screening for fetal chromosomal abnormalities. Obstetrics and gynecology. 2007; 109(1):217-27. PMID: 17197615.
3. Bianchi DW, Parker RL, Wentworth J, Madankumar R, Saffer C, Das AF, et al. DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med. 2014; 370(9):799-808. Epub 2014/02/28. doi: 10.1056/NEJMoa1311037 PMID: 24571752.
4. American Congress of Obstetricians and Gynecologists. Committee Opinion No. 545: Noninvasive prenatal testing for fetal aneuploidy. Obstetrics and gynecology. 2012; 120(6):1532-4. Epub 2012/11/22. doi: 10.1097/01.AOG.0000423819.85283.f4 PMID: 23168792.
5. Benn P, Borell A, Chiu R, Cuckle H, Dugoff L, Faas B, et al. Position statement from the Aneuploidy Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenatal diagnosis. 2013; 33(7):622-9. doi: 10.1002/pd.4139 PMID: 23616385.
6. Dar P, Curnow KJ, Gross SJ, Hall MP, Stosic M, Demko Z, et al. Clinical experience and follow-up with large scale single-nucleotide polymorphism-based noninvasive prenatal aneuploidy testing. American journal of obstetrics and gynecology. 2014; 211(5):527 e1-e17. doi: 10.1016/j.ajog.2014.08.006 PMID: 25111587.
7. Pergament E, Cuckle H, Zimmermann B, Banjevic M, Sigurjonsson S, Ryan A, et al. Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstetrics and gynecology. 2014; 124(2 Pt 1):210-8. doi: 10.1097/AOG.0000000000000363 PMID: 25004354; PubMed Central PMCID: PMC4144440.
8. Benn P. Non-invasive prenatal testing using cell free DNA in maternal plasma: recent developments and future prospects. J Clin Med. 2014; 3:537-65.
9. Gregg AR, Gross SJ, Best RG, Monaghan KG, Bajaj K, Skotko BG, et al. ACMG statement on noninvasive prenatal screening for fetal aneuploidy. Genet Med. 2013; 15(5):395-8. doi: 10.1038/gim.2013.29 PMID: 23558255.
10. Norton ME, Jacobsson B, Swamy GK, Laurent LC, Ranzini AC, Brar H, et al. Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med. 2015; 372(17):1589-97. doi: 10.1056/NEJMoa1407349 PMID: 25830321.
11. Zhang H, Gao Y, Jiang F, Fu M, Yuan Y, Guo Y, et al. Noninvasive Prenatal Testing for Trisomy 21, 18 and 13-Clinical Experience from 146,958 Pregnancies. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015. doi: 10. 1002/uog.14792 PMID: 25598039.
12. Benn P, Borrell A, Chiu RW, Cuckle H, Dugoff L, Faas B, et al. Position statement from the Chromosome Abnormality Screening Committee on behalf of the Board of the International Society for Prenatal Diagnosis. Prenatal diagnosis. 2015. doi: 10.1002/pd.4608 PMID: 25970088.
13. Palomaki GE, Kloza EM, Lambert-Messerlian GM, Haddow JE, Neveux LM, Ehrich M, et al. DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med. 2011; 13(11):913-20. Epub 2011/10/19. doi: 10.1097/GIM.0b013e3182368a0e PMID: 22005709.
14. Garfield SS, Amstrong BA. Clinical and Cost Consequences of Incorporating a Novel Non-Invasive Prenatal Test into the Diagnostic Pathway for Fetal Trisomies. J Manag Care Med. 2012; 15(2):34-41.
15. Song K, Musci TJ, Caughey AB. Clinical utility and cost of non-invasive prenatal testing with cfDNA analysis in high-risk women based on a US population. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2013; 26(12):1180-5. doi: 10.3109/14767058.2013.770464 PMID: 23356557; PubMed Central PMCID: PMC3741020.
16. Ohno M, Caughey A. The role of noninvasive prenatal testing as a diagnostic versus a screening tool-A cost-effectiveness analysis. Prenatal diagnosis. 2013; 33(7):630-5. Epub 2013/05/16. doi: 10.1002/pd.4156 PMID: 23674316.
17. Cuckle H, Benn P, Pergament E. Maternal cfDNA screening for Down syndrome-A cost sensitivity analysis. Prenatal diagnosis. 2013; 33(7):636-42. doi: 10.1002/pd.4157 PMID: 23674341.
18. O'Leary P, Maxwell S, Murch A, Hendrie D. Prenatal screening for Down syndrome in Australia: costs and benefits of current and novel screening strategies. The Australian & New Zealand journal of obstetrics & gynaecology. 2013; 53(5):425-33. doi: 10.1111/ajo.12136 PMID: 24090461.
19. Okun N, Teitelbaum M, Huang T, Dewa CS, Hoch JS. The price of performance: a cost and performance analysis of the implementation of cell-free fetal DNA testing for Down syndrome in Ontario, Canada. Prenatal diagnosis. 2014; 34(4):350-6. doi: 10.1002/pd.4311 PMID: 24395030.
20. Morris S, Karlsen S, Chung N, Hill M, Chitty LS. Model-based analysis of costs and outcomes of noninvasive prenatal testing for Down's syndrome using cell free fetal DNA in the UK National Health Service. PLoS One. 2014; 9(4):e93559. doi: 10.1371/journal.pone.0093559 PMID: 24714162; PubMed Central PMCID: PMC3979704.
21. Ayres AC, Whitty JA, Ellwood DA. A cost-effectiveness analysis comparing different strategies to implement noninvasive prenatal testing into a Down syndrome screening program. The Australian & New Zealand journal of obstetrics & gynaecology. 2014; 54(5):412-7. doi: 10.1111/ajo.12223 PMID: 25196262.
22. Neyt M, Hulstaert F, Gyselaers W. Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis. BMJ Open. 2014; 4(11):e005922. doi: 10.1136/bmjopen-2014-005922 PMID: 25380810; PubMed Central PMCID: PMC4225226.
23. Beulen L, Grutters JP, Faas BH, Feenstra I, van Vugt JM, Bekker MN. The consequences of implementing non-invasive prenatal testing in Dutch national health care: a cost-effectiveness analysis. European journal of obstetrics, gynecology, and reproductive biology. 2014; 182:53-61. doi: 10.1016/j. ejogrb.2014.08.028 PMID: 25238658.
24. Walker BS, Jackson BR, LaGrave D, Ashwood ER, Schmidt RL. A cost-effectiveness analysis of cell free DNA as a replacement for serum screening for Down syndrome. Prenatal diagnosis. 2015; 35(5): 440-6. doi: 10.1002/pd.4511 PMID: 25273838.
25. Evans MI, Sonek JD, Hallahan TW, Krantz DA. Cell-free fetal DNA screening in the USA: a cost analysis of screening strategies. Ultrasound in obstetrics & gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2015; 45(1):74-83. doi: 10.1002/uog.14693 PMID: 25315699.
26. Fairbrother G, Burigo J, Sharon T, Song K. Prenatal screening for fetal aneuploidies with cell-free DNA in the general pregnancy population: a cost-effectiveness analysis. The journal of maternal-fetal & neonatal medicine: the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstet. 2015:1-5. doi: 10. 3109/14767058.2015.1038703 PMID: 26000626.
27. Martin JA, Hamilton BE, Ventura SJ, Osterman MJK, Mathews TJ. Births: Final Data for 2011. June 28, 2013 ed. Hyattsville, MD: National Center for Health Statistics.: CDC; 2013.
28. Palomaki GE, Knight GJ, Ashwood ER, Best RG, Haddow JE. Screening for down syndrome in the United States: results of surveys in 2011 and 2012. Archives of pathology & laboratory medicine. 2013; 137(7):921-6. doi: 10.5858/arpa.2012-0319-CP PMID: 23808464.
29. Wald NJ, Rodeck C, Hackshaw AK, Walters J, Chitty L, Mackinson AM. First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS). Journal of medical screening. 2003; 10(2):56-104. Epub 2004/01/30. PMID: 14746340.
30. Spencer K, Nicolaides KH. A first trimester trisomy 13/trisomy 18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free beta-hCG and PAPP-A. Prenatal diagnosis. 2002; 22(10): 877-9. PMID: 12378569
31. Centers for Medicare and Medicaid Services. Physician Fee Schedule 2014 [1 Dec 2014]. Available: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/PFSlookup/index.html.
32. Centers for Medicare and Medicaid Services. Clinical Diagnostic Laboratory Fee Schedule 2014 [1 December 2014]. Available: http://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/ClinicalLabFeeSched/index.html.
33. Benn P, Wright D, Cuckle H. Practical strategies in contingent sequential screening for Down syndrome. Prenatal diagnosis. 2005; 25(8):645-52. doi: 10.1002/pd.1215 PMID: 16049988.
34. Shaffer BL, Caughey AB, Norton ME. Variation in the decision to terminate pregnancy in the setting of fetal aneuploidy. Prenatal diagnosis. 2006; 26(8):667-71. doi: 10.1002/pd.1462 PMID: 16724363.
35. Biggio JR Jr., Morris TC, Owen J, Stringer JS. An outcomes analysis of five prenatal screening strategies for trisomy 21 in women younger than 35 years. American journal of obstetrics and gynecology. 2004; 190(3):721-9. doi: 10.1016/j.ajog.2003.09.028 PMID: 15042005.
36. Waitzman NJ, Romano PS, Scheffler RM. Estimates of the economic costs of birth defects. Inquiry. 1994; 31(2):188-205. PMID: 8021024.
37. Saenger P, Wikland KA, Conway GS, Davenport M, Gravholt CH, Hintz R, et al. Recommendations for the diagnosis and management of Turner syndrome. The Journal of clinical endocrinology and metabolism. 2001; 86(7):3061-9. doi: 10.1210/jcem.86.7.7683 PMID: 11443168.
38. Agency for Healthcare Research and Quality. Healthcare Cost and Utilization Project (HCUP) Kids' Inpatient Database (KID) (2006 and 2009) 2009 [23 December 2014]. Available: http://www.hcup-us. ahrq.gov/overview.jsp.
39. Rava RP, Srinivasan A, Sehnert AJ, Bianchi DW. Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy x. Clinical chemistry. 2014; 60(1):243-50. doi: 10.1373/clinchem. 2013.207951 PMID: 24046201.
40. Nicolaides KH, Syngelaki A, del Mar Gil M, Quezada MS, Zinevich Y. Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. Fetal diagnosis and therapy. 2014; 35(3):212-7. doi: 10. 1159/000355655 PMID: 24135152.
41. Palomaki GE, Kloza EM, Lambert-Messerlian GM, van den Boom D, Ehrich M, Deciu C, et al. Circulating cell free DNA testing: are some test failures informative? Prenatal diagnosis. 2015; 35(3):289-93. doi: 10.1002/pd.4541 PMID: 25449554.
42. Wallerstein R, Jelks A, Garabedian MJ. A new model for providing cell-free DNA and risk assessment for chromosome abnormalities in a public hospital setting. Journal of pregnancy. 2014; 2014:962720. doi: 10.1155/2014/962720 PMID: 25101177; PubMed Central PMCID: PMC4102090.